GameStop Reports Bitcoin Holdings Along With Financial Results
GameStop (GME) has reported its new Bitcoin (BTC) holdings alongside its first-quarter financial results.The Texas-based video game retailer announced earnings per share (EPS) of $0.09 U.S., which was ahead of the $0.04 U.S. consensus expectation of analysts. However, revenue for the quarter came in at $732.4 million U.S., which fell short of the consensus Wall Street estimate of $754.2 million U.S.The company also reported an improved operating margin of -1.5%, which was up from -5.7% in the same quarter of 2024. GameStop’s free cash flow at the end of the quarter totaled $189.6 million U.S., which was a big improvement from negative -$114.7 million U.S. a year ago.Along with its financial results, GameStop disclosed that it bought 4,710 Bitcoins between May 3 and June 10 of this year. It’s not known what the average purchase price of the Bitcoin was. However, GameStop’s BTC holdings are currently worth $516.6 million U.S. based on the current price of Bitcoin.GameStop announced previously that it planned to begin buying and holding cryptocurrencies, adopting a similar playbook to software developer turned serial BTC acquirer Strategy (MSTR).The company made its first Bitcoin investment in May of this year.The stock of GameStop has declined 2% in 2025 to trade at $30.15 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


